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Abstract
Background: Despite nearly complete vaccine coverage, a small number of fully vaccinated children in the
Netherlands have experienced invasive disease caused by Haemophilus influenzae serotype b (Hib). This increase
started in 2002, nine years after the introduction of nationwide vaccination in the Netherlands. The capsular
polysaccharide of Hib is used as a conjugate vaccine to protect against Hib disease. To evaluate the possible rise
of escape variants, explaining the increased number of vaccine failures we analyzed the composition of the
capsular genes and the expressed polysaccharide of Dutch Hib strains collected before and after the introduction
of Hib vaccination.
Results: The DNA sequences of the complete capsular gene clusters of 9 Dutch Hib strains were assessed and
two variants, designated type I and type II were found. The two variants displayed considerable sequence
divergence in the hcsA and hcsB genes, involved in transport of capsular polysaccharide to the cell surface.
Application of hcsA type specific PCRs on 670 Hib strains collected from Dutch patients with invasive Hib disease
showed that 5% of the strains collected before 1996 were type II. No endogenous type II Hib strains were isolated
after 1995 and all type II strains were isolated from 0–4 year old, non-vaccinated children only. Analysis of a
worldwide collection of Hib strains from the pre-vaccination era revealed considerable geographic differences in
the distribution of the type I and type II strains with up to 73% of type II strains in the USA. NMR analysis of type
I and type II capsule polysaccharides did not reveal structural differences. However, type I strains were shown to
produce twice as much surface bound capsular polysaccharide.
Conclusion: Type II strains were only isolated during the pre-vaccination era from young, non-vaccinated
individuals and displayed a lower expression of capsular polysaccharide than type I strains. The higher
polysaccharide expression may have provided a selective advantage for type I strains resulting in the rapid
elimination of type II from the Dutch Hib population after introduction of nationwide Hib vaccination. However,
this phenomenon does not explain the increase in the number of Hib vaccine failures in the Netherlands.
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Background
Worldwide the number of cases of invasive disease caused
by Haemophilus influenzae serotype b (Hib) has dramati-
cally decreased after the introduction of vaccines com-
posed of the conjugated polysaccharide capsule of the
pathogen. In the Netherlands Hib vaccination was intro-
duced in 1993 resulting in a decrease in incidence of inva-
sive Hib disease among children younger than 5 years of
age from 28.7 per 100,000 in 1992 to 0.4 in 2001 [1].
Despite nearly complete vaccine coverage, a small number
of fully vaccinated children in the Netherlands have expe-
rienced invasive Hib disease. In 2002 the incidence of vac-
cine failures in Dutch children aged 0–4 years increased
from 0.4 per 100,000 in the years 1996 to 2001 to 1.3 per
100,000 in 2002 [2,1]. In only a few patients underlying
conditions were found that might have contributed to
vaccine failure. Half of the patients had adequate anti-PRP
titers at the onset of disease, which is similar to what is
found in the same age group of the healthy population.
All vaccine failure patients responded well to revaccina-
tion with the Hib vaccine yielding high anti-PRP titers,
indicating there was no impairment of the immune sys-
tem. Since 2002 the annual number of cases of invasive
Hib disease among 0–4 year old children in the Nether-
lands has remained approximately the same [3].
In the United Kingdom a somewhat more pronounced
rise in vaccine failures has been observed particularly in
children 1–4 years of age and this was believed to be
caused by inadequate antibody titers against Hib due to
waning immunity. To compensate for the reduced anti-
body titers, a catch-up campaign, designed to boost
immunity in children aged 6 months to 4 years of age, was
implemented in the United Kingdom [4]. Furthermore,
an additional Hib booster in the second year of life has
now been implemented in the United Kingdom vaccina-
tion schedule [5]. A Hib booster vaccination at 11 months
of age has been part of the Dutch Hib vaccination sched-
ule since its introduction in 1993. This booster should
have prevented waning immunity in children and sug-
gests that reduced antibody titers may not have been the
cause of the increased number of vaccine failures observed
in the Netherlands. Therefore, changes in the properties,
e.g. virulence factors, of circulating Hib strains could not
excluded. The major virulence factor of Hib is the polysac-
charide capsule, a polymer of ribose ribitol phosphate
(PRP), which is also the antigen used for Hib vaccination.
The production and export of the polysaccharide capsule
of Hib is encoded by 10 genes located in single locus con-
sisting of 3 distinct regions. The first region contains 4 bex
genes involved in the export of the capsular polysaccha-
ride, the second region carries 4 bcs genes which are con-
sidered to be involved in the actual synthesis of the
polysaccharide and the third region carrying 2 hcs genes is
now also considered to be involved in the export of the
polysaccharide to the surface of the cell [6,7].
Changes of the genes in the capsular gene cluster locus
may lead to an altered capsule of the Hib. If this would be
the case in the currently circulating Hib strains the vaccine
induced immunity may not provide optimal protection
causing an increased incidence of invasive Hib disease
among vaccinated children in the Netherlands. This
prompted us to analyze the composition of the genes
encoding for capsular polysaccharide, the structure of the
encoded polysaccharide and of the level of expressed cap-
sular polysaccharide in Hib strains isolated before and
after the introduction of nationwide Hib vaccination in
the Netherlands.
Results
Sequence analysis of the Hib capsule locus
The DNA sequence of the locus carrying the genes encod-
ing the components required to synthesize and export the
capsular polysaccharide was determined. Sequencing of
the complete capsular gene cluster was performed on 9
Hib strains isolated from Dutch patients with invasive dis-
ease, on reference strain Eagan and on strain 1482 which
has been used for the production of the Hib conjugate
vaccine (Table 1). The 9 clinical isolates were selected
because they represented pre- and post-vaccination strains
and because they were isolated from vaccinated and non-
vaccinated patients of various ages. Analysis revealed that
the DNA sequence of the complete 17 kb capsule gene
cluster was identical among 8 of the 9 Dutch Hib strains.
The gene cluster of the divergent Hib strain, isolated from
an 18 months old non-vaccinated patient in 1994, dif-
fered considerably from that of the other 8 strains (Fig. 1).
We designated strains with the composition of the gene
cluster found in the 8 strains as Hib type I and the strain
with the aberrant gene cluster as Hib type II. Sequence
analysis of the gene cluster of the Eagan strain and of the
Hib vaccine strain 1482, yielded sequences that were vir-
tually identical to the Dutch type II strain, with the excep-
tion of a single, silent C→T mutation at position 194 of
the  hcsA  gene. The differences between the DNA
sequences of the type I and type II capsule gene clusters
were restricted to bcs3 (a single nucleotide polymorphism
(SNP)), the bcs4 (12 SNPs + 24 bp deletion in type II),
hcsA (93 SNPs) and hcsB (24 SNPs + 24 bp deletion in
type II) genes. The 24 bp deletion in the bcs4 gene of type
II strains results in an 8 amino acids loss in the C-terminal
part of the product encoded by this gene. The 24 bp dele-
tion of the hcsB gene was caused by a 2 bp deletion in the
intergenic region between hcsA and hcsB, resulting in the
loss of the ATG start codon of hcsB. However, a C→G SNP
created a new start codon in the now 24 bp shorter hcsB
gene. As a result HcsB in type II strains have an 8 amino
acid shorter signal sequence.BMC Microbiology 2008, 8:35 http://www.biomedcentral.com/1471-2180/8/35
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Comparison with the sequences in the publicly available
databases revealed that sequences of the capsule gene
clusters from 3 different Hib strains have been published
[6]. Although the sequences were not identical, they were
highly similar (e.g. 17 bp difference between type II
sequences DQ368335 and AF54213) and it was clear that
the capsule gene cluster in one of these 3 strains, a Hib
minus strain isolated from a patient in the USA, is of type
I (acc.no. AF549212). The capsule gene clusters of the
other 2 strains, a regular Hib strain and a Hib minus
strain, have a type II composition (acc.no. AF549213 and
AF549210). Currently, the Sanger Institute, in collabora-
tion with Dr. Derrick Crook and Prof. Richard Moxon, is
sequencing the genome of a Hib isolate (strain 10810)
from a meningitis patient from the United Kingdom [8].
The nucleotide sequence of the capsular genes in the
unfinished genome sequence of this strain 10810 is iden-
tical to that of the type I capsular gene cluster found in the
Dutch strains.
Distribution of Hib type I and type II strains
The availability of the DNA sequence of the 2 types of cap-
sular gene clusters enabled us to design 2 primer sets tar-
geting  hcsA  that could discriminate between the two
capsular genotypes in a PCR. This PCR was used to ana-
lyze 670 Hib isolates obtained from patients with invasive
Hib disease in the Netherlands. Of 388 strains isolated
during the period 1983–1995 and of 282 strains isolated
during the period 1996–2006, a type II associated hcsA
gene was found in 20 (5%) and 1 (0.4%) isolates, respec-
tively (Table 2), yielding a statistically highly significant
difference in distribution (χ2, p ≤ 0.001). Remarkably,
Schematic representation of the differences between the type I and type II Hib capsular gene clusters Figure 1
Schematic representation of the differences between the type I and type II Hib capsular gene clusters. The top 
part of the figure shows the genetic organization of the capsular gene cluster of Hib. The figure displays a single copy of the 
gene cluster with the fused truncated insertion element IS1016 and the incomplete bexA gene on the left hand side. The com-
plete bexA gene and part of the bexB gene, present in the second copy of the gene cluster are depicted at the right hand side. 
The region containing the bcs4, hcsA and hcsB genes are displayed as a blow up. The vertical lines indicate nucleotide substitu-
tions, closed circles denote amino acid substitutions and Δ indicate deletions.
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Table 1: Strains used for sequencing the capsule gene cluster
Strain number Age patient Isolated from Vaccine failure Capsule locus type
Hib from pre-vaccination era
H1990-0614 14 months CSF No I
H1991-1722 3 years CSF No I
H1992-2218 10 months CSF No I
H1994-0151 18 months CSF No II
Hib from post-vaccination era
H2000-1692 71 years Blood No I
H2000-1882 2 years CSF Yes I
H2001-1610 3 years Blood Yes I
H2002-2067 8 months CSF Yes I
H2002-2328 73 years Blood No I
Other Hib
Vaccine strain 1482 No II
Strain Eagan No IIBMC Microbiology 2008, 8:35 http://www.biomedcentral.com/1471-2180/8/35
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with the exception of a single Hib strain isolated in 2005,
type II strains were not detected among the Hib strains
isolated after 1995, which is only 2 years after the intro-
duction of the Hib vaccine in the national vaccination
program. The type II Hib strain isolated in 2005 was iso-
lated from a 3 months old, non-vaccinated Chinese child
that was adopted by Dutch parents and did not represent
an endogenous strain. All type II strains were isolated
from non-vaccinated children ranging from 0–4 years of
age, not a single type II strain was isolated from a patient
older than 4 years of age. Again this difference in distribu-
tion is statistically significant (χ2, p ≤ 0.001). There was no
statistically significant association between the distribu-
tion of the capsular genotypes and the materials from
which they were isolated (CSF or blood).
Assessment by the type I and type II specific PCRs of a col-
lection of Hib strains isolated during the pre-vaccination
period between 1980 and 1990 from patients in various
regions in the world revealed remarkable differences in
geographic distribution of type I and type II (Table 3). Of
the 232 Dutch Hib isolates from this time period 11 were
type II (5%). None of the 17 Hib isolates from patients
from other parts of Europe carried the type II hcsA gene.
The proportion of the type II strains among the strains
from the various global regions varied from 47% for
strains from the African continent, 4% for Asian strains,
8% in strains from Australia and 43% of the isolates from
Cuba. However, the largest proportion of type II strains
was found among Hib strains isolated from patients in the
United States where 40 of the 55 strains were type II
(73%).
Sequence variation of the hcsA gene
We found only 2 variants of the capsule gene cluster in the
11 strains from which the complete gene cluster was
sequenced, suggesting very limited variation of the capsu-
lar genes. To verify this finding we determined the DNA
sequence of hcsA  PCR products obtained from a large
number of type I and type II strains. In total the DNA
sequences of the hcsA PCR products obtained from 111
Dutch type I strains collected during the time period 1984
to 2006 were determined. The DNA sequences of 109 of
the 111 PCR products were identical. Only two strains,
one isolated in 1992 from a 99 year old patient and the
other in 1996 from 4 months non-vaccinated old child,
had an A→G SNP at position 597 of the type I hcsA gene
that did not lead to an amino acid substitution. The DNA
sequences of the hcsA PCR products from all 21 type II
strains in the strain collection were determined and all
products had identical sequences. In addition, the
sequences of the hcsA PCR products of 14 type I and 13
type II Hib strains collected during the pre-vaccination era
in various other parts of the world were also determined.
This revealed very limited variation in the hcsA sequence
of type I strains. As, The A→G SNP at position 597 of the
type I hcsA gene which was also found in the Dutch Hib
strains, appeared to be present in a strain from South-
Africa, in one from Malaysia, one from Vietnam and in 2
strains from the USA. Furthermore, 2 strains from Cuba
contained 2 SNPs: an A→G SNP at position 736 and a
C→A SNP at position 806. Both base pair changes lead to
amino acid substitutions. Remarkably, these SNPs corre-
spond to the sequences found in the type II hcsA gene. All
PCR products obtained from the 13 type II strains had
sequences identical to the previously determined type II
hcsA sequence.
Association between capsular type and genotype
Assessing 667 of the Dutch Hib strains by MLVA [9],
revealed that the type II strains were not randomly distrib-
uted among the 47 MLVA types. Of the 22 type II strains,
13 (59%) had MLVA type 40 which is the predominant
type among Dutch strains, one strain belonged to MLVA
type 19 and the remaining 8 strains formed a separate
branch of MLVA types not found among type I strains
(Fig. 2). Of the collection of Dutch strains available, 247
Hib strains were analyzed by MLST [10,9] and none of the
19 type II strains among this collection were of sequence
type 6 (ST-6), which was by far the predominant sequence
Table 3: Distribution of capsular genotypes in various geographic 
regions among Hib strains collected during the pre-vaccination 
era 1980–1990
Capsule locus type
Region No. of strains I II % II
The Netherlands 232 221 11 5
Europe (Finland & Switzerland) 17 16 0 0
Africa (The Gambia & South 
Africa)
17 9 8 47
Asia (Malaysia & Vietnam) 26 25 1 4
Australia 12 11 1 8
Cuba 7 4 3 43
U S A 5 5 1 54 07 3
Table 2: Distribution of the type I and type II strains stratified 
over time and age groups
Capsule locus type
Time period of 
isolation
Patient's age No. of strains I II
1983–1995 All 388 368 20
≤ 4 years 255 235 20
> 4 years 133 133 0
1996–2006 All 282 281 1
≤ 4 years 143 142 1
> 4 years 139 139 0BMC Microbiology 2008, 8:35 http://www.biomedcentral.com/1471-2180/8/35
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type (75%) among the 247 Hib strains (Fig 2). This sug-
gested an inverse relationship between capsule locus type
II and ST-6. To assess such a possible inverse relationship
we amplified and subsequently sequenced the MLST fucK
locus for all 89 type II Hib strains from our collection,
including strains isolated in other countries. All strains
with a fucK allele other than allele number 5 were classi-
fied as not having ST-6. Only a few type II Hib strains
yielded fucK allele 5 and for these strains the MLST pgi
locus was amplified and subsequently sequenced. None
of these strains carried pgi allele 7. As pgi allele 7 and fucK
allele 5 are part of the ST-6 allelic profile this showed that
none of the type II isolates had ST-6, demonstrating an
absolute inverse relationship between capsule locus type
II and ST-6 genotype for the 89 type II Hib strains
included in this study.
Composition of the capsular polysaccharide obtained 
from type I and type II strains
The sequence differences between the homologous genes
in the type I and type II capsule loci prompted us to ana-
lyze the structure of capsular polysaccharides produced by
type I and type II strains. NMR analysis of polysaccharides
isolated from the culture supernatant of two type I and
two type II strains showed no obvious differences between
NMR spectra of the polysaccharides obtained from the
two types, suggesting the structure of the polysaccharide
from the two types is identical (Fig. 3). The few very minor
The 1H-NMR spectra of PRP samples obtained from type II and type I Hib strains Figure 3
The 1H-NMR spectra of PRP samples obtained from type II and type I Hib strains. NMR profiles of type I Hib strain 
H1990-0614 and type II Hib strain H1994-0151. The minor absorptions at 3.5–3.65 ppm are caused some residual glycerol.
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Minimum spanning trees of 667 strains on which MLVA was performed and of 247 Hib strains analyzed by MLST Figure 2
Minimum spanning trees of 667 strains on which MLVA was performed and of 247 Hib strains analyzed by 
MLST. Each circle represents a different type. The size of the circle indicates the number of strains with this particular type. 
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differences in the NMR spectra were not associated with
the two capsular genotypes.
Level of expression of polysaccharide capsule in type I and 
type II Hib strains
In order to detect differences in the level of capsule
polysaccharide expression by capsule locus type I and type
II strains, polysaccharide production was assessed by an
inhibition ELISA. Four type I and 4 type II strains were
analyzed to determine the level of polysaccharide produc-
tion. The results showed that absorption of serum with
cell fractions of the type I cultures caused more inhibition
than with cells of type II strains. Using a standard curve
based on inhibition with serial dilutions of purified
polysaccharide, we deduced that the type I cells contained
approximately twice as much capsular polysaccharide as
type II cells (Fig. 4). This result was reproducible (the
same experiment was performed three times) and statisti-
cally significant (ANOVA analysis, p ≤ 0.002). The culture
supernatants from type I and type II cultures contained
significantly more polysaccharide than the cellular frac-
tions. However, the amount of polysaccharide in the cul-
ture supernatant from type I strains did not differ
significantly from that of type II strains. This indicates that
the amount of shed polysaccharide in type I and type II
strains is the same, but that the total amount of polysac-
charide produced in type I strains is higher.
Possible differences in the level of polysaccharide produc-
tion were also assessed in a serum bactericidal assay. The
SBA was performed using heat inactivated serum obtained
from adult human volunteers that were immunized with
Hib conjugate vaccine. Serial dilutions of the serum were
used in SBAs using type I and type II Hib as target cells.
Twice as much serum was required to kill 90% of the type
I target cells in the SBA compared to the amount required
to kill type II target cells (Fig. 5). Remarkably, the use of
type I strains as target cells yielded a more pronounced
pro-zone effect than type II strains. Cell fractions of the 4
type I and 4 type II strains used in the above described
inhibition ELISA were used to perform absorption of a
high titer serum from a human volunteer. Absorption of
the serum with cells from the type I strains reduced its SBA
titer from 1:2,048 to 1:32. In contrast, the serum sample
retained an SBA titer of 1:128 after absorption with type II
cells (Table 4.). The same 4-fold difference in reduction of
SBA titer was observed if either type I or a type II Hib
strains were used as target cells for the SBA. Other high
titer serum samples absorbed with type I cells yielded sim-
ilar results. Absorption with cell fractions of isogenic type
I or type II Hib minus variants did not reduce the SBA
titer, showing the observed reduction is caused by the
polysaccharide and not by other components of the bac-
teria.
Electron microscopy of type I and type II strains
To determine if the observed difference in capsular expres-
sion could also be visualized on the surface of the bacte-
rial cells, electron microscopy (EM) was performed. For
this purpose overnight grown type I (H1976-0705) and
type II (Eagan) cultures and their isogenic capsule minus
variants were stained and fixed to visualize capsular struc-
tures on the surface of the cells. Examination by electron
microscopy revealed that type I cells had a thinner capsu-
Table 4: Reduction in SBA of a high titer serum sample absorbed 
with type I or type II Hib cells
SBA titer
Type I target cells Type II target cells
Unabsorbed 1:2,048 1:4,096
Absorbed with type I cells 1:32 1:64
Absorbed with type II cells 1:128 1:256
Expression of the Hib polysaccharide capsule of type I and  type II strains as measured by inhibition ELISA Figure 4
Expression of the Hib polysaccharide capsule of type 
I and type II strains as measured by inhibition ELISA. 
The graph displays the OD values obtained in the ELISA after 
inhibition by the cell fraction and the culture supernatant 
obtained from type I and type II strains. Inhibition was per-
formed with 3 different dilutions of the antigens. Each bar 
denotes the average of the values obtained with 4 different 
strains and the error bars indicate the standard error. Red 
bars, inhibition by type I cells; yellow, inhibition by type II 
cells; dark blue, inhibition by type I culture supernatant; light 
blue, inhibition by type II culture supernatant. Note that in 
this graph higher OD values represent lower polysaccharide 
expression.
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lar layer than the cells from type II strain (Fig. 6). The aver-
age thickness of the capsular layer of type I cells and type
II cells was 42 nm (range 16–104 nm, SE 13 nm) and 72
nm (range 23–152 nm, SE 23 nm), respectively. However,
the capsule of type I cells was more electron dense,
appearing as a more compact layer on the cell surface
compared the capsule of the type II cells.
Discussion
In this study, we determined the composition of the genes
encoding the components required for the synthesis and
transport of the polysaccharide capsule of Hib strains iso-
lated from patients with invasive disease in the Nether-
lands. We found that two variants of the capsular gene
cluster exist and we designated these as type I and type II.
Type I strains were found to carry approximately twice as
much capsular polysaccharide on the surface of the cells as
did type II strains. Of the strains, isolated from patients
with invasive Hib disease in the Netherlands during the
time period 1983–1995, 5% were type II. After 1995, only
2 years after the introduction of the Hib vaccine in the
Dutch national immunization program, type II strains
were no longer isolated from Dutch patients with invasive
Hib disease.
The variation between the capsular gene cluster sequences
of type I and type II strains was predominantly found in
the hcsA and hcsB genes. The nucleotide sequences of bex,
bcs1 and bcs2 of type I and of type II were identical. Only
one SNP was found in bcs3 and a few SNPs in bcs4, some
of which are leading to amino acid substitutions. The bcs
genes are believed to be involved in the biosynthesis of
the polysaccharide and even small alterations in these
genes could change the composition of the polysaccha-
ride produced. However, NMR analysis of the polysaccha-
rides isolated from type I and type II strains revealed no
structural differences between the two types. Recently,
Sukupolvi-Petty and colleagues demonstrated that the
products of the hcsA and hcsB genes facilitate transport of
capsular polysaccharide across the outer membrane [7].
Inactivation of hcsA  alone resulted in accumulation of
polysaccharide in the periplasm and a partial decrease in
surface-associated polysaccharide, whereas inactivation of
hcsB alone or of both hcsA and hcsB resulted in accumula-
tion of polysaccharide in the periplasm and complete loss
of surface associated polysaccharide. It is therefore feasi-
ble that alterations in the hcsA and hcsB genes would influ-
ence the degree of export of the capsular polysaccharide to
Comparison of capsular structures of type I and type II Hib  cells by electron microscopy Figure 6
Comparison of capsular structures of type I and type 
II Hib cells by electron microscopy. Overnight cultures 
were stained for the presence of polysaccharide capsule, 
fixed, counterstained and cut into ultrathin sections. All 
images were made at 67,000× magnification.
Type I
Type II
Type I -Hib- variant
Type II -Hib- variant
SBA with serial dilutions of a high titer serum using type I and  type II Hib strains as target cells Figure 5
SBA with serial dilutions of a high titer serum using 
type I and type II Hib strains as target cells. The serum 
sample was diluted over a range of 1:8 (23) to 1:262,144 (218) 
and mixed with type I or with type II bacteria in the presence 
of baby rabbit complement. The SBA titer using the type I 
strain as target is 1:2,048 (211), whereas the type II target 
strain yields a titer of 1:4,096 (212). The pro-zone effect, 
growth in the presence of high concentrations of serum, is 
more pronounced for the type I strain.
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the surface of the Hib cells or the efficiency of retaining
the exported polysaccharide on the surface. We showed
that the type I hcsA and hcsB genes and putative encoded
proteins differed considerably in composition from those
of the type II strains. These differences did not lead to a
detectable difference in structure between the two capsu-
lar genotypes. However, we provided evidence that, at
least  in vitro, the amount of capsular polysaccharide
retained on the surface of studied type I strains was twice
as high as that in type II strains. In an inhibition ELISA,
cells obtained from type I cultures caused significantly
more inhibition than cells from type II cultures. Similar
results were obtained in an SBA where absorption of
serum samples with type I cells resulted in a four-fold
higher reduction of SBA titer compared to absorption with
type II cells. Furthermore, there always was a pronounced
pro-zone effect when type I strains were used in the SBA
while only a modest pro-zone effect was seen when type
II strains were used as target cells in the SBA. The pro-zone
effect is thought to reflect a steric hindrance caused by
high concentrations of bound antibodies which in turn is
caused by high concentrations of antigen [11]. This would
confirm the higher density of capsular polysaccharide on
the surface of type I cells. Electron microscopy revealed
that the capsular layers of type I Hib cells were thinner, yet
denser than that of type II cells, that could suggest that in
type I strains more polysaccharide may bound per surface
area.
Cerquetti and colleagues showed that a significantly
greater proportion of strains isolated from vaccine failures
in the United Kingdom carried multiple copies of the cap
gene cluster [12]. As shown by Noel and colleagues, the
presence of multiple copies of the cap locus would result
in more polysaccharide production and decreased com-
plement-mediated lysis [13]. Hence, higher antibody lev-
els may be required to protect against Hib disease caused
by strains with multiple copies of the cap gene cluster. We
have shown that type I strains may produce more capsular
polysaccharide and therefore higher antibody titers may
be required to eliminate type I Hib compared to type II
strains. All Dutch type II strains used in this study were
exclusively isolated from non-vaccinated children
younger than 5 years of age and consequently, all vaccine
failures in the Netherlands were caused by type I strains.
This suggests that type II Hib strains may be less well
equipped to cause invasive disease in hosts that have been
immunized by vaccination or by natural exposure to Hib
and may explain why the type II strains seem to have
become extinct in the Netherlands after the introduction
of the Hib vaccine. The fact that the proportion of type II
strains among the Hib population before the introduction
of the vaccine was only 5% possibly would have contrib-
uted to the rapid elimination.
The type I and type II strains appear to represent two dis-
tinct groups within the Hib population. This is particu-
larly obvious from the MLST analysis of the Hib strains.
The Hib population displays a relatively low degree of
genetic diversity when analyzed by MLST. In the Nether-
lands 75% of the Hib strains typed by MLST had ST-6.
Remarkably, none of the Dutch type II strains were ST-6,
suggesting an inverse relationship between capsular geno-
type II and ST-6. This inverse relationship was confirmed
by our finding that none of the type II strains obtained
from other countries had ST-6. MLVA analysis of the
Dutch Hib collection also revealed a non-random distri-
bution of the type II strains corroborating the distinct
nature of the type II strains.
It is unclear what has caused the polymorphism of the two
gene clusters in Hib strains, but it is unlikely that this
reflects a gradual change in the capsular genes. DNA
sequence analysis of the complete capsular gene clusters
of 11 Hib strains revealed the presence of only 2 types of
sequences. Sequence analysis of a large number of hcsA
PCR products obtained from Dutch type I and type II Hib
and from strains collected in various other parts of the
world confirmed the very limited variability in type I
strains and the complete lack thereof in those from type II
strains. Possibly Hib strains have acquired the hcsA and
hcsB genes from other capsulated H. influenzae or other
bacterial species through lateral transfer and recombina-
tion. Thus far only the hcsA and hcsB genes of serotype b
and serotype f strains have been sequenced [14]. Compar-
ison of the type I and type II hcs gene sequences of the Hib
strains with the hcs  sequences of the serotype f strain
shows that these are similar but distinct sequences and
that Hib has not acquired the hcs genes from H. influenzae
serotype f.
Conclusion
In summary, this investigation has shown that two vari-
ants of Hib strains exist that differ considerably in the
DNA sequence of the genes hcsA and hcsB. These genes are
involved in the transport of the major virulence factor, the
capsular polysaccharide, to the surface of the Hib cell. We
show that the type I isolates used in this study carried
more surface bound capsular polysaccharide than type II
isolates. Type II strains were isolated from 0–4 year old,
non-vaccinated patients suggesting type II only causes
invasive disease in hosts that have not yet mounted anti-
bodies against the Hib capsule. Before the introduction of
the Hib vaccine 5% of the Hib isolates from Dutch
patients with invasive Hib disease were type II and after
nationwide Hib vaccination this type was no longer
found. The lower capsule production in type II strains
may have caused a selective disadvantage explaining the
rapid disappearance of type II strains from the Dutch Hib
population. However, this change in the composition ofBMC Microbiology 2008, 8:35 http://www.biomedcentral.com/1471-2180/8/35
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the Hib population does not explain why the Netherlands
has experienced an increase in the number of vaccine fail-
ures since 2002 and further investigation is required to
explain the observed increase.
Methods
Bacterial strains and serum samples
For this study we included 670 Hib strains collected dur-
ing the years 1983–2006 by the Netherlands Reference
Laboratory for Bacterial Meningitis (NRBM) from Dutch
patients with invasive disease. Of these strains 409 were
isolated from CSF and 245 strains were isolated from
blood. The remainder of the strains was isolated from
other normally sterile compartments such as joints. Hib
strains are sent to the NRBM on a voluntary basis, but it is
estimated that this results in coverage of more than 85%
of all cases of invasive Hib disease in the Netherlands. The
strain collection contained all available 282 Hib strains
isolated from 1996–2006 and 388 randomly selected
strains from the time period 1983–1996. From each year
of latter time period, we included approximately 20 Hib
strains isolated from 0–4 year old children and approxi-
mately 10 strains from patients older than 4 years, 75% of
which were 18 years or older. In addition, we used Hib ref-
erence strain Eagan and vaccine strain 1482 kindly pro-
vided by Dr. R. Schneerson. Dr. L. van Alphen kindly
provided us with 134 Hib strains from different locations
in the world collected during the years 1980–1990. How-
ever, the nature of these strains, carriage or invasive dis-
ease, was unknown. Of the Dutch Hib strains 667 were
typed by multiple-locus variable number tandem repeats
analysis (MLVA) [9] and 237 by multi-locus sequence typ-
ing (MLST) [10,9].
Positive serum samples for SBA and ELISA were obtained
from 5 volunteers who received a single dose of ActHib
vaccine (Aventis Pasteur MSD, Lyon, France) and a nega-
tive control serum was obtained from a volunteer who
was not immunized (ages ranged from 25 to 57 years).
Serum samples were collected 2 months after vaccination,
aliquoted and stored at -20°C until use.
DNA sequencing of the capsular gene cluster
For sequencing of the complete Hib capsule gene cluster
PCR products creating overlapping fragments of the gene
cluster were used. Sequence reactions were performed
with the ABI PRISM BigDye Terminator cycle sequencing
kit v3.1 (Applied Biosystems, Foster City, Calif.) and ana-
lyzed on an AB3700 DNA sequencer. DNA sequences
have been submitted to GenBank under acc.no.
DQ368334 and acc.no. DQ368335.
Hib capsular genotype specific PCR
For PCR detection of the type I hcsA oligonucleotide prim-
ers HiHcsA12667F-I (GTACTTGTCATTGACCAAACTTT)
and HiHcsA13116R-I (GGTATATTGAAAGTATGCTGCAT)
yielding a 450 bp PCR product were used. To detect type
II hcsA primers HiHcsA12668F-II (TGCTTGTCATCGAT-
CAAA) and HiHcsA13484R-II (ACTAAAGAAAGGGGT-
GCAA) yielding a 817 bp PCR product were used. Two
separate PCRs were performed in AB9700 PCR machines
using the following protocol: 1 μl of 1:10 diluted heat-
treated H. influenzae lysate was added to a 24 μl mixture
containing 10 pmol of each primer and 12.5 μl diluted
HotStar Taq mastermix (Qiagen, Hilden, Germany). The
PCR program used was 15 min at 95°C, followed by 30
cycles of amplification that consisted of 30 sec at 95°C, 1
min at 52°C, and 1 min at 72°C and a final 7 min at
72°C. Strains were screened by type I PCR and all samples
that did not yield a PCR product were analyzed again in
both the type I and type II PCR. All strains for which the
hcsA PCR products were used for sequence analysis were
analyzed in both PCRs.
Serum bactericidal activity
Functional antibodies binding to the PRP capsule of Hib
and fixing complement onto the bacterial surface were
measured by an slightly modified assay for serum bacteri-
cidal activity (SBA) described by Romero-Steiner et al.
[15]. Ten μl of heat inactivated serum was mixed with 20
μl of the diluted Hib suspension and incubated for 15 min
at 35°C at 5% CO2. Thereafter, 25 μl of Hanks buffer (Life
Technologies, Grand Island, N.Y., USA) with 2% Fildes
(BBL, Becton Dickinson and Co., Sparks, Md., USA) and
25 μl of baby rabbit complement (Pel-Freez, Brown Deer,
Wis., USA) was added and the mixture was incubated for
1 h at 35°C at 5% CO2. From the mixture 5 μl aliquots
were applied onto 12 × 12 cm square culture plates filled
with Brain Hearth Infusion agar, supplemented with Hae-
mophilus test medium supplement (Oxoid, Haarlem, The
Netherlands). SBA titers were defined as the serum dilu-
tion that resulted in >90% killing of the Hib culture used
for the assay.
Inhibition of the serum bactericidal activity
Hib suspensions used for absorption assays were obtained
from 100 ml overnight cultures, grown in supplemented
Brain Hearth Infusion broth. Fifty ml of culture was cen-
trifuged for 10 min at 3000 g, and the pellet was resus-
pended in 5 ml 150 Mm NaCl after which the bacteria
were killed by a 10 min incubation at 65°C. In the SBA
absorption assays 10 μl aliquots of heat inactivated serum
samples were pre-absorbed with 10 μl heat killed Hib sus-
pensions. The mixture was incubated for 1 h at 37°C fol-
lowed by an overnight incubation at 4°C. The mixture
was then centrifuged for 10 min at 10,000 g and the super-
natant was used for SBA. To ensure the various cultures
contained the same number of bacteria, real time quanta-
tive PCR and protein quantification were used to assess
and adjust the number of bacteria in each culture used forBMC Microbiology 2008, 8:35 http://www.biomedcentral.com/1471-2180/8/35
Page 10 of 11
(page number not for citation purposes)
absorption. Cell suspensions and supernatants were aliq-
uoted and stored at -20°C until use.
Type b polysaccharide inhibition ELISA
To assess the level of the capsular polysaccharide expres-
sion of the various Hib strains an inhibition ELISA was
designed. For this purpose an ELISA, described by Phipps
et al. [16] and used to determine antibody titers against
Hib polysaccharide was adapted. In contrast to the origi-
nal method 1:20,000 diluted horse-radish-peroxidase
labeled Protein A/G (Pierce, Rockford, USA) and TMB
substrate solution (110 mM NaAc pH 5.5, 166 μg/ml
3,3',5,5' tetramethylbenzidine, 0.006% H2O2) were used.
Reactions were stopped after 5 min using 2 M H2SO4, and
values were read at 450 nm in a Biotek EL312e ELISA
reader. In order to relate the degree of inhibition to the
amount polysaccharide, serial dilutions of purified
polysaccharide (HBO-HA, National Institute for Biologi-
cal Standards and Control, Hertfordshire, United king-
dom) with known concentration were added to HBO-HA-
coated microtiter plates after which a single dilution of a
high titer serum sample was added to all wells and incu-
bated for 1 h at room temperature. Subsequently the
ELISA was performed as described above.
Hib suspensions used for the inhibition ELISA were
obtained from the same overnight grown type I and type
II cultures as those used for the absorption of the SBA. Five
ml culture was centrifuged as described above and the pel-
let was reconstituted in 5 ml PBS after which Hib in both
supernatant and cellular fraction were heat killed. To
ensure the various cultures contained the same number of
bacteria, real time quantative PCR and protein quantifica-
tion were used to assess and adjust the number of bacteria
in each culture used for absorption. To assess the polysac-
charide content in Hib strains, the above described cells
and culture supernatants from type I and type II strains
were pre-treated with 0.1% SDS for 30 min at 60°C and
used in the inhibition ELISA described above.
Electron microscopy of Hib strains
Fixation and capsular stain were basically performed
according to the lysine-acetate-based formaldehyde-glu-
taraldehyde ruthenium red-osmium fixation procedure
(LLR-methode) method [17]. A 30 ml overnight culture of
Hib grown in supplemented BHI was centrifuged for 10
min at 1800 g. Half of the supernatant was discarded and
the remaining cells were fixed in paraformaldehyde and
glutaraldehyde in the presence of ruthenium red after
which they were imbedded in agarose by centrifugation,
dehydrated using graded series of ethanol, impregnated in
the epoxy resin glycidether 100 and finally polymerized in
BEEM capsules at 60°C. Ultrathin sections were cut with
a diamond knife, contrasted with 2% uranyl acetate,
counterstained with lead citrate and examined in a FEI
Tecnai12 transmission electron microscope.
Purification of the Hib polysaccharide
The capsular polysaccharide of various Hib strains was
isolated and purified from liquid cultures as described
before with some modifications [18]. Strains were cul-
tured 22 hours at 35°C in 500 ml supplemented brain
heart infusion broth. The culture was centrifuged for 30
min at 3000 g and 0.65% cetyl trimethyl ammonium bro-
mide (CTAB) was added to the culture supernatant. After
overnight incubation at 4°C the solution was centrifuged
for 30 min. at 3000 g. The pellet was dissolved in 50 ml
solution containing 1 M NaCl, 5 mM NaAc pH5.2 and
72% ethanol was added. After overnight incubation the
solution was centrifuged for 30 min at 3000 g and the pel-
let was dissolved in 10 ml PBS (200 mM NaCl, 4.5 mM
KCl, 17 mM phosphate buffer pH7.4). The solution was
then purified on a Hi Prep 16/60 Sephacryl S300 high res-
olution column (GE Healthcare, Uppsala, Sweden) using
PBS at a flow rate of 0.5 ml/min. The purified polysaccha-
ride was eluted from the column in a 12 ml volume
directly after the void volume. The purified polysaccha-
ride was precipitated by adding 1 M NaCl, 5 mM NaAc
pH5.2 and 72% ethanol and overnight incubation at 4°C.
After centrifugation for 30 min. at 3000 g the pellet was
dissolved in water, dialyzed extensively against water in a
slide-a-lyzer with a 7000 Da cut-off (Pierce Biotechnol-
ogy, Rockford, USA) and dried in a SpeedVac. The average
yield of this procedure was 5–10 mg of purified PRP.
Nuclear magnetic resonance analysis of Hib 
polysaccharide
The purified PRP was analyzed by nuclear magnetic reso-
nance (NMR) as described before [19]. Briefly, samples
were dissolved in deuterated water (D2O), containing
0.075% (w/w) of trimethylsilyl-[D4]-propanoate sodium
salt (Sigma-Aldrich, Zwijndrecht, The Netherlands).
NMR-spectra were recorded on a JEOL JNM-ECP400 FT
NMR system (JEOL, Tokyo, Japan) at 9.4 T using a pre-sat-
uration pulse to lower the residual water peak.
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